超声引导下平阳霉素联合聚桂醇硬化治疗94例囊性淋巴管畸形的疗效

目的 回顾性分析超声引导下平阳霉素联合聚桂醇经皮硬化治疗囊性淋巴管畸形(cLM)的疗效和安全性。 方法 共纳入cLM患者94例,年龄0.5~43岁,儿童患者86例,发病时间在2岁之前75例,巨囊型32例、微囊型31例、混合型31例。 结果 治疗后随访时间3.7~39.2个月,平均治疗次数2.8次,病灶体积减小的有效率为78.7%,症状缓解的有效率为82.1%,患者及家属的满意率为85.1%,14例患者出现不良反应,未出现肺纤维化、过敏等严重不良反应,7例复发患者再次给予治疗,效果好。 结论 超声引导下平阳霉素联合聚桂醇经皮硬化治疗cLM是一种安全有效的方式,值得临床推广。

Efficacy of ultrasound-guided sclerotherapy with pingyangmycin and lauromacrogol in 94 cases of cystic lymphatic malformation

Objective To retrospectively analyze the efficacy and safety of ultrasound-guided percutaneous sclerotherapy with pingyangmycin and lauromacrogol in the treatment of cystic lymphatic malformation(cLM). Methods A total of 94 cLM patients aged 0.5-43 years were enrolled, 75 of whom had onset before 2 years of age(32 cases of macrocystic type, 31 cases of microcystic type, and 31 cases of mixed type). Results The patients received an average of 2.8 times of treatments. During the follow-up of 3.7-39.2 months, the lesion volume reduction was 78.7%, the effective rate of symptom relief was 82.1%, and the satisfaction rate of patients and their families was 85.1%. Side effects occurred in 14 patients, but no serious adverse reactions such as pulmonary fibrosis or allergies were observed. Recurrence occurred in 7 patients, who received a second treatment and had good outcomes. Conclusion Ultrasound-guided percutaneous sclerotherapy with pingyangmycin and lauromacrogol is effective and safe in the treatment of cystic lymphatic malformation, and it is worthy of clinical promotion.